Featured Articles

Solid Biosciences Inc., a clinical-stage company focused on genetic medicines for neuromuscular and cardiac diseases, announced it has received Fast Track designation from the U.S. Food…
Read More...

A new potential treatment for generalised myasthenia gravis (gMG), a rare and debilitating autoimmune neuromuscular disease, has shown promising results in a large international…
Read More...

Sanofi has announced an agreement to acquire London-based biotechnology company Vicebio Ltd, expanding its presence in the respiratory vaccine space. The deal brings with it a promising…
Read More...

AstraZeneca announces $50 billion of investment in the United States by 2030, building on America’s global leadership in medicines manufacturing and R&D. This investment is expected…
Read More...

Astellas Pharma Inc. announced the signing of a memorandum of understanding (MoU) with the Korea Institute of Startup and Entrepreneurship Development (KISED), a government-backed…
Read More...

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to ENHERTU (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab for the…
Read More...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to SAR446597, a one-time intravitreal gene therapy developed by Sanofi for the treatment of geographic…
Read More...

GSK announced that the U.S. Food and Drug Administration (FDA) has approved a new prefilled syringe presentation of Shingrix, the company’s vaccine for the prevention of shingles…
Read More...

Boehringer Ingelheim and LEO Pharma have entered an exclusive global license and transfer agreement to commercialize and further develop SPEVIGO (spesolimab), a monoclonal antibody…
Read More...

Merck, known as MSD outside the U.S. and Canada, announced that it will acquire Verona Pharma plc in a $10 billion deal, strengthening its presence in the respiratory disease space. The…
Read More...

AbbVie and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI),announced an exclusive licensing agreement for IGI's lead…
Read More...

GSK plc has finalized its acquisition of efimosfermin alfa from Boston Pharmaceuticals, a promising investigational therapy targeting steatotic liver disease (SLD). Efimosfermin is a…
Read More...

Merck, known as MSD outside the U.S. and Canada, announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to a supplemental Biologics License…
Read More...

Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic (linvoseltamab-gcpt) to treat adult patients…
Read More...

Vetter, a leading, globally operating Contract Development and Manufacturing Organization (CDMO), celebrated the start of construction for its new clinical manufacturing site in Des…
Read More...

AbbVie and Capstan Therapeutics, Inc. announced a definitive agreement under which AbbVie will acquire Capstan, including CPTX2309, a potential first-in-class in vivo tLNP anti-CD19…
Read More...

Novartis has officially completed its acquisition of Regulus Therapeutics Inc., solidifying its strategic focus on advancing treatments for renal diseases. With the closing of the deal,…
Read More...

Gilead Sciences, Inc. and Kymera Therapeutics, Inc. have announced an exclusive option and license agreement aimed at advancing a novel class of cancer treatments: molecular glue…
Read More...

Eli Lilly and Company announced that the U.S. FDA has approved a label update for Amyvid (florbetapir F 18 injection) for intravenous use. Amyvid is used for brain imaging to estimate…
Read More...

Novo Nordisk announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion to update the label of Ozempic…
Read More...